ADC Therapeutics

ADC Therapeutics develops antibody drug conjugates with capabilities spanning clinical development, manufacturing, and commercialization. Its first PBD-based ADC received accelerated FDA approval and conditional approval from the European Commission.

ADC Therapeutics is advancing a focused portfolio using its pyrrolobenzodiazepine (PBD) technology.

ADC Therapeutics says it is committed to providing employees with health and wellness support for their professional and personal well-being.

Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company.

ADC Therapeutics funds resources, education, programs, and events for external independent not-for-profit organizations, including patient advocacy groups, professional medical associations, and other charitable organizations.

ADC Therapeutics says its mission is to confront cancer using its science to bring targeted therapies to patients and their families.

ADC Therapeutics’ interactive portal accepts unsolicited requests for sponsorships, corporate memberships, and non-CME grants aligned with its mission, vision, corporate objectives, and compliance policies.

The notice says the Privacy Policy applies to information collected on the form and that recipients may unsubscribe at any time.

ADC Therapeutics’ technology includes an FDA-approved anti-CD19 ADC.

The privacy policy covers personal data processed by ADC Therapeutics SA and its affiliates during business activities, including browsing websites they administer.

The website is owned by ADC Therapeutics SA, whose registered office is in Epalinges, Switzerland. Accessing and browsing the website constitutes acceptance of its terms and conditions.